AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Nasus Pharma Ltd.
XASE · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI AK-F95C27B22A
3.49▲ 0.26 (8.05%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
3.23
Day's Range
3.09 – 3.59
52-Week Range
1.98 – 9.50
Volume
35.2K
Avg Volume
22.9K
Share Statistics
Shares Outstanding
Employees
7
Exchange
XASE
Listed
2025-08-13
Share count as of December 31, 2025

Nasus Pharma Ltd. (NSRX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Nasus Pharma Ltd. (NSRX)
What is Nasus Pharma Ltd.'s Market Cap?
Nasus Pharma Ltd.'s Market Cap is $31.5M, based on as-reported figures from SEC (XBRL) filings.
What is Nasus Pharma Ltd.'s Enterprise Value?
Nasus Pharma Ltd.'s Enterprise Value is $23.6M, based on as-reported figures from SEC (XBRL) filings.
What is Nasus Pharma Ltd.'s Price / Sales?
Nasus Pharma Ltd.'s Price / Sales is 0.0×, based on as-reported figures from SEC (XBRL) filings.
What is Nasus Pharma Ltd.'s EV / Revenue?
Nasus Pharma Ltd.'s EV / Revenue is 0.0×, based on as-reported figures from SEC (XBRL) filings.
What is Nasus Pharma Ltd.'s Revenue (TTM)?
Nasus Pharma Ltd.'s Revenue (TTM) is $1.2B, based on as-reported figures from SEC (XBRL) filings.
What is Nasus Pharma Ltd.'s Net Income (TTM)?
Nasus Pharma Ltd.'s Net Income (TTM) is -$10.5M, based on as-reported figures from SEC (XBRL) filings.
What is Nasus Pharma Ltd.'s Diluted EPS (TTM)?
Nasus Pharma Ltd.'s Diluted EPS (TTM) is -1.17, based on as-reported figures from SEC (XBRL) filings.
What is Nasus Pharma Ltd.'s Net Debt?
Nasus Pharma Ltd.'s Net Debt is -$7.8M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · NSRXAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Total operating expenses
Operating loss from continuing operations
Change in fair value of convertible securities
Other expenses, net
Loss from continuing operations
Income from Discontinued Operations
Net loss
Basic
Diluted